ArticleMolecular therapy. Oncology2026

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Agnes Bonifacius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.